Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis
Reason given: Poor accrual rate
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- TBF Genie Tissulaire
- Trial code
- NCT06034262
- Record updated
- 6 October 2026
- Original description
The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of PIP joint osteoarthritis.Read full original descriptionShow less
Evaluation of the Treatment of Symptomatic Proximal InterPhalangeal (PIP) Joint Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition
The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of PIP joint osteoarthritis.
Inclusion: Male or female; age between 18 and 75 years; Patient with symptomatic PIPJ OA; Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention; Patient with a QuickDash score > 33 points (converted to 50%); Patient with pain, at rest, in the PIPJ ≥ 4/10 on a VAS; Patient who received the study information and provided consent; Member or beneficiary of a national health insurance plan.
Exclusion: Patient with signs of neuropathy with functional disorders such as hyperesthesia; Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia; Pregnant or breastfeeding woman; woman without effective contraception; Person confined by a judicial or administrative decision; Adult subjected to legal protection measures or unable to provide his/her consent.